|
Protandim is a patented〔 dietary supplement marketed by LifeVantage Corporation (; formerly LifeLine Therapeutics, Lifeline Nutraceuticals, and Yaak River Resources, Inc), a Utah-based multilevel marketing company.〔LifeVantage Corporation(【引用サイトリンク】 title=FAQs - LifeVantage )〕 The manufacturers of Protandim claim the product can indirectly increase antioxidant activity by upregulating endogenous antioxidant factors such as the enzymes superoxide dismutase (SOD) and catalase, as well as the tripeptide glutathione. Like all dietary supplements, Protandim has not been evaluated by the U.S. Food and Drug Administration (FDA) and "is not intended to diagnose, treat, cure, or prevent any disease."〔This statement or disclaimer is required by US law (DSHEA) when a manufacturer makes a structure/function claim on a dietary supplement label within the United States of America. (【引用サイトリンク】 title=FDA: Overview of Dietary Supplements )〕 == Product history== In 2003, Lifeline Therapeutics, a privately held Denver-based nutraceutical licensing and marketing company, entered into a joint agreement with Massachusetts biotechnology company CereMedix for the rights to market CMX-1152, an experimental peptide-based compound, under the brand name "Protandim" (also sometimes referred to at that time as "Rholen," "Rejuven8r" and "ependymin").〔 CereMedix was a ten percent owner of Lifeline and members of the CereMedix management board served on Lifeline’s board of directors. CMX-1152 was claimed to upregulate the production of the endogenous antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase, and to offset the ageing process, potentially allowing people to live up to the age of 120.〔 CMX-1152 was due to be marketed as an over the counter anti-aging pill in June 2004 after completing human clinical trials. However, plans to market the CMX-1152 version of Protandim fell through and in April 2004 Lifeline Therapeutics announced that it would instead be marketing a different (non-peptide) dietary supplement under the name “Protandim CF” (to distinguish it from the peptide version initially developed by Cermedix). The new version of Protandim, a combination of 5 common herbal ingredients including turmeric and green tea was invented following “months of extensive research and development” by Lifeline employees Paul Myhill and William Driscoll (a former oil company executive), who together hold the patent on the product, and it was officially launched in February 2005. Myhill and Driscoll resigned from the company later that year.〔 Like CMX-1152, the herbal version of Protandim that supplanted it was marketed by Lifeline as an "anti-aging" supplement that increases the body’s antioxidant defenses by upregulating superoxide dismutase, catalase, and glutathione peroxidase. According to the company, the product was initially sold through retail channels such as GNC; however, in 2009, after several consecutive years of multimillion dollar losses, the company, which by then was doing business under the name LifeVantage, stopped marketing Protandim through retailers and switched to multilevel marketing, selling it instead through a network of commissioned independent distributors exclusively. According to LifeVantage, the move from retail to multi-level marketing was prompted by the January 2008 hiring of David W. Brown, (formerly CEO and president of Metabolife) as the company's CEO and president. Beginning in 2005, Protandim was produced under a manufacturing agreement with The Chemins Company of Colorado Springs, Colorado.〔(【引用サイトリンク】title= LIFEVANTAGE CORP - 10KSB/A (06 January 2006 ) )〕 In July 2008, LifeVantage entered into a new manufacturing agreement with Cornerstone Research & Development to produce Protandim, and with Wasatch Product Development to produce a Protandim-based skin cream (TrueScience).〔http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=8164388-16511-132473&type=sect&dcn=0001193125-11-258536〕 In 2006, biochemist Joe M. McCord joined the LifeVantage board of directors as the company’s Director of Science.〔http://www.allbusiness.com/company-activities-management/board-management/5376294-1.html〕 McCord, who is listed by the SEC as a LifeVantage insider shareholder,〔http://secwatch.com/mccord-joe-m〕 served as a spokesperson for Protandim and was responsible for distributor training and product research.〔 Under the terms of his 2011 employment agreement, McCord received $529,994 in direct compensation as well as a 50-cent commission on every bottle of Protandim sold.〔(【引用サイトリンク】url=http://www.sec.gov/Archives/edgar/data/849146/000119312511258536/d225491d10k.htm )〕 During his tenure with the company, McCord co-authored 12 studies on Protandim.〔〔〔〔〔〔〔〔〔〔〔 He went on to serve as LifeVantage’s Chief Scientific Officer from June 2011 until September 2012, and then became a member of the company's science advisory board. LifeVantage announced McCord’s retirement in June 2013.〔http://globenewswire.com/news-release/2013/06/25/556132/10037495/en/Dr-Joe-McCord-LifeVantage-Corporation-s-First-Chief-Science-Officer-Retires-From-Company.html〕 Under the terms of the separation agreement, McCord was to receive a payment of $1.7 million from the company.〔 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Protandim」の詳細全文を読む スポンサード リンク
|